Laurent Roche

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1890927/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Estimating net survival: the importance of allowing for informative censoring. Statistics in Medicine, 2012, 31, 775-786.	0.8	74
2	Cancer net survival on registry data: Use of the new unbiased Poharâ€Perme estimator and magnitude of the bias with the classical methods. International Journal of Cancer, 2013, 132, 2359-2369.	2.3	62
3	Prostate Focal Peripheral Zone Lesions: Characterization at Multiparametric MR Imaging—Influence of a Computer-aided Diagnosis System. Radiology, 2014, 271, 761-769.	3.6	60
4	HIV-1 Load Comparison Using Four Commercial Real-Time Assays. Journal of Clinical Microbiology, 2011, 49, 292-297.	1.8	54
5	The Net Chance of a Longer Survival as a Patient-Oriented Measure of Treatment Benefit in Randomized Clinical Trials. JAMA Oncology, 2016, 2, 901.	3.4	47
6	An extension of generalized pairwise comparisons for prioritized outcomes in the presence of censoring. Statistical Methods in Medical Research, 2018, 27, 1230-1239.	0.7	43
7	A multilevel excess hazard model to estimate net survival on hierarchical data allowing for non-linear and non-proportional effects of covariates. Statistics in Medicine, 2016, 35, 3066-3084.	0.8	37
8	Changes in the dynamics of the excess mortality rate in chronic phase-chronic myeloid leukemia over 1990-2007: a population study. Blood, 2011, 118, 4331-4337.	0.6	33
9	Flexible and structured survival model for a simultaneous estimation of non-linear and non-proportional effects and complex interactions between continuous variables: Performance of this multidimensional penalized spline approach in net survival trend analysis. Statistical Methods in Medical Research, 2019, 28, 2368-2384	0.7	24
10	Multi-Dimensional Penalized Hazard Model with Continuous Covariates: Applications for Studying Trends and Social Inequalities in Cancer Survival. Journal of the Royal Statistical Society Series C: Applied Statistics, 2019, 68, 1233-1257.	0.5	23
11	An assessment of the benefit-risk balance of FOLFIRINOX in metastatic pancreatic adenocarcinoma. Oncotarget, 2016, 7, 82953-82960.	0.8	22
12	Describing the association between socioeconomic inequalities and cancer survival: methodological guidelines and illustration with population-based data. Clinical Epidemiology, 2018, Volume 10, 561-573.	1.5	21
13	survPen: an R package for hazard and excess hazard modelling with multidimensional penalized splines. Journal of Open Source Software, 2019, 4, 1434.	2.0	19
14	Multidimensional penalized splines for incidence and mortality-trend analyses and validation of national cancer-incidence estimates. International Journal of Epidemiology, 2020, 49, 1294-1306.	0.9	11
15	Neuropsychological and neuroanatomical phenotype in 17 patients with cystinosis. Orphanet Journal of Rare Diseases, 2020, 15, 59.	1.2	10
16	One-step partial or complete caries removal and bonding with antibacterial or traditional self-etch adhesives: study protocol for a randomized controlled trial. Trials, 2016, 17, 404.	0.7	9
17	Trends in net survival from breast cancer in six European Latin countries: results from the SUDCAN population-based study. European Journal of Cancer Prevention, 2017, 26, S85-S91.	0.6	9
18	Comparative Study of Neoadjuvant Chemotherapy With and Without Zometa for Management of Locally Advanced Breast Cancer With Serum VEGF as Primary Endpoint: The NEOZOL Study. Clinical Breast Cancer, 2018, 18, e1311-e1321.	1.1	8

LAURENT ROCHE

#	Article	IF	CITATIONS
19	New insights into survival trend analyses in cancer population-based studies: the SUDCAN methodology. European Journal of Cancer Prevention, 2017, 26, S9-S15.	0.6	7
20	Adherence to cysteamine in nephropathic cystinosis: A unique electronic monitoring experience for a better understanding. A prospective cohort study: CrYSTobs. Pediatric Nephrology, 2021, 36, 581-589.	0.9	7
21	Relationship between adverse drug reactions and unlicensed/off-label drug use in hospitalized children (EREMI): A study protocol. Therapie, 2021, 76, 675-685.	0.6	7
22	Trends in net survival from cervical cancer in six European Latin countries: results from the SUDCAN population-based study. European Journal of Cancer Prevention, 2017, 26, S92-S99.	0.6	5
23	Performance of two formal tests based on martingales residuals to check the proportional hazard assumption and the functional form of the prognostic factors in flexible parametric excess hazard models. Biostatistics, 2017, 18, 505-520.	0.9	5
24	Diagnostic value and relative weight of sequence-specific magnetic resonance features in characterizing clinically significant prostate cancers. PLoS ONE, 2017, 12, e0178901.	1.1	5
25	Trends in net survival from prostate cancer in six European Latin countries: results from the SUDCAN population-based study. European Journal of Cancer Prevention, 2017, 26, S114-S120.	0.6	4
26	Trends in net survival from 15 cancers in six European Latin countries: the SUDCAN population-based study material. European Journal of Cancer Prevention, 2017, 26, S3-S8.	0.6	3
27	Place of a new radiological index in predicting pulp exposure before intervention for deep carious lesions. Oral Radiology, 2021, , 1.	0.9	3
28	How do age and social environment affect the dynamics of death hazard and survival in patients with breast or gynecological cancer in France?. International Journal of Cancer, 2022, 150, 253-262.	2.3	3
29	Author's reply to: Estimating net survival in population-based cancer studies. International Journal of Cancer, 2013, 133, 522-523.	2.3	0
30	Trends in net survival from corpus uteri cancer in six European Latin countries: results from the SUDCAN population-based study. European Journal of Cancer Prevention, 2017, 26, S100-S106.	0.6	0